Outpatient versus inpatient treatment for acute pulmonary embolism
Cochrane Database of Systematic Reviews
Current very low quality evidence from one published RCT did not provide sufficient evidence to assess efficacy and safety of outpatient versus inpatient treatment for acute PE in overall mortality, bleeding and recurrence of PE adequately.
A Randomized Trial of Intraarterial Treatment for Acute Ischemic Stroke
New England Journal of Medicine
RCT (n=500) found intraarterial treatment (IAT) given within 6 hours after stroke led to shift in distribution of score on modified Rankin scale at 90 days vs. usual care in favour of IAT (OR 1.67; 95% CI, 1.21 to 2.30) and likewise in proportion who were functionally independent.
Biospace Inc.
The submission was based on results from the LEOPOLD (Long-Term Efficacy Open-Label Program in Severe Hemophilia A Disease) clinical trials, which evaluated rFVIII administered in two-to-three-times-per-week prophylaxis dosing regimens.
National Institute for Health and Care Excellence
Dabigatran etexilate is recommended, within its marketing authorisation, as an option for treating and for preventing recurrent deep vein thrombosis and pulmonary embolism in adults.
European Heart Journal
In the ARISTOTLE study, major bleeds were associated with an increased risk of death, ischaemic stroke, or MI, especially following intracerebral haemorrhage. This risk was similarly elevated regardless of whether the patient was treated with apixaban or warfarin.
The above records have been identified by UKMi and feature in the NICE Medicines Awareness Service. Further details on this service can be found at:
http://www.evidence.nhs.uk/about-evidence-services/content-and-sources/medicines-information/new-medicines-awareness-services
